根据上海证券交易所发布的上市公司分行业信息披露指引《上市 公司自律监管指引第3号——行业信息披露之第六号——医药制造》 及《关于做好主板上市公司2025年半年度报告披露工作的重要提醒》 相关要求，现将公司2025年半年度主营业务分行业、分产品情况数据 披露如下： 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－073 华润双鹤药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 单位：元 币种：人民币 华润双鹤药业股份有限公司 董 事 会 2025 年 8 月 23 日 注：公司从战略定位角度出发对华润紫竹等部分产品的划分进行 细化调整，重述上年同期数据。 本公告之经营数据未经审计，提醒投资者审慎使用上述数据。 特此公告。 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 | 营业收入比 上年同期增 | 营业成 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年11月13日，复星惟实及复星惟盈再度抛出减持计划，拟自2024年12月5日至2025年3月4日以集中 竞价方式和大宗交易方式合计减持公司股份不超过686.78万股，占公司总股本3.00%，减持期满后最终 实际减持227.36万股，占公司总股本的1%。 截至最新一次减持计划实施之前，复星惟实及复星惟盈合计持有公司约6.54%的股份，累计减持股份占 其上市时持股数的比例达54.52%。本次如满额减持，二者持股比例将进一步降至3.54%。 沪指乘风破浪，接连刷新高点，成功站上3700点大关，市场情绪一片火热。然而，与指数"高歌猛进"形 成微妙对比的是，上市公司重要股东减持公告正悄然增多。据统计，8月1日至今，沪深两市已有超过30 家生物医药上市公司发布了股东减持计划，其中减持比例大于或等于3%的公司如下图所示。 | 公告时间 | 公司 | 梶特主体 | 糖特股数(万股) | 减持股数占总股 本比例 | | --- | --- | --- | --- | --- | | 8月7日 | 力诺药包 | 5%以上股东、高管 | 840.73 ...

Core Insights - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide [1] - During the "14th Five-Year Plan" period, the National Medical Products Administration (NMPA) approved 204 innovative drugs and 265 innovative medical devices, with 50 innovative drugs and 49 innovative medical devices approved in the first seven months of this year [1] - The NMPA has optimized the review and approval process for urgently needed foreign new drugs, accelerating the market entry of pediatric and rare disease medications, approving 387 pediatric drugs and 147 rare disease drugs since the beginning of the "14th Five-Year Plan" [1] Industry Quality and Safety - The NMPA focuses on ensuring drug quality and safety, particularly for vaccines and blood products, implementing regular risk assessment and management in key areas such as rural and urban fringe regions [2] - The agency conducts over 200,000 drug inspections, 20,000 medical device inspections, and 20,000 cosmetic inspections annually, ensuring comprehensive coverage of selected products in national procurement [2] - China supports open cooperation in the pharmaceutical industry, facilitating global clinical trials and shortening the global market entry timeline for drugs, while also encouraging foreign investment in domestic production of original drugs and high-end medical equipment [2]

根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类 和Ⅲ类会议，就关键阶段重大问题进行沟通交流，Ⅲ类会议一般安排在申请后75日内召开。 来源：金融界 苏州新波生物技术有限公司，成立于2000年，位于苏州市，是一家以从事医药制造业为主的企业。企业 注册资本6000万人民币，实缴资本6000万人民币。 通过天眼查大数据分析，苏州新波生物技术有限公司共对外投资了1家企业，参与招投标项目222次，知 识产权方面有商标信息2条，专利信息79条，此外企业还拥有行政许可179个。 金融界8月22日消息，据CDE官网沟通交流公示，于8月22日收到苏州新波生物技术有限公司申请的"III 类会议"，当前状态"处理中"。 主要股东信息显示，苏州新波生物技术有限公司由瑞孚迪生物医学（上海）有限公司持股75%、Wallac Oy持股25%。 ...

Group 1: Business Environment Optimization - The time to open a restaurant has been reduced from 37 days to 15 days, and the number of documents required for business information changes has been streamlined from 23 to 6 [1] - Since the beginning of the "14th Five-Year Plan," there has been a net increase of 19.999 million enterprises and 33.946 million individual businesses in China [2] - The State Administration for Market Regulation has implemented the "Fair Competition Review Regulations" to address issues such as "malicious competition" in investment promotion and has eliminated 4,218 policies that hinder the flow of resources [2][3] Group 2: Consumer Rights Protection - During the "14th Five-Year Plan," the market regulation departments handled 89.028 million complaints, recovering economic losses of 21.71 billion yuan for consumers [3] - The national consumer association received 5.749 million complaints, recovering 5.78 billion yuan in economic losses [3] - The State Administration for Market Regulation has conducted nationwide actions to destroy counterfeit and inferior goods, covering over 200 categories with a total value of 2.79 billion yuan [3] Group 3: Platform Economy Regulation - The platform economy is undergoing a critical transformation, with new risks such as algorithm abuse and competition disorder emerging [4] - Since the "14th Five-Year Plan," the State Administration for Market Regulation has deleted 4.541 million pieces of illegal product information and handled 105,000 internet-related cases [4] - Future efforts will focus on enhancing regulatory frameworks for the platform economy while promoting healthy development [4] Group 4: Pharmaceutical Industry Development - A total of 204 innovative drugs and 265 innovative medical devices have been approved since the "14th Five-Year Plan," with 50 innovative drugs approved in the first seven months of this year [6] - The pharmaceutical industry in China ranks second globally, with approximately 30% of innovative drugs under research worldwide [6] - The National Medical Products Administration is supporting the high-quality development of the pharmaceutical industry through various expedited approval channels [6][7]

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index rising 0.13% to 3,771 points, marking a 10-year high[13] - U.S. stocks fell for the fifth consecutive day, with the Dow Jones down 0.34% to 44,785 points and the S&P 500 down 0.40% to 6,370 points[7] - European markets exhibited divergence, with the Stoxx 600 index closing nearly flat, while the UK FTSE 100 rose 0.23%[7] Economic Indicators - U.S. manufacturing expanded at the fastest pace since 2022, while initial jobless claims indicated a weak labor market[4] - The Federal Reserve officials expressed hawkish views ahead of Chairman Powell's speech at Jackson Hole, raising concerns about inflation[4] Commodity and Currency Movements - International oil prices fluctuated, with WTI crude oil rising 0.5% to $63.52 per barrel and Brent crude oil up 1.2% to $67.67 per barrel[26] - The U.S. dollar index increased by 0.4%, while gold prices saw a slight decline[26] Company Performance - Futu Holdings reported a 74.9% year-on-year increase in revenue for H1 2025, reaching HKD 10.006 billion, with a Non-GAAP net profit growth of 101.7%[7] - AAC Technologies' net profit for H1 2025 grew by 63% to CNY 876 million, exceeding market expectations[12] Stock Market Trends - The Hang Seng Index fell 0.24%, with major tech stocks declining, while healthcare stocks showed strength with a 2.2% increase[9] - In Latin America, the S&P Mexico IPC Index rose 0.76%, driven by gains in the healthcare sector[7] Bond Market Insights - U.S. Treasury yields fluctuated, with the 2-year yield rising 4.4 basis points to 3.79% following strong PMI data[29] - Standard & Poor's maintained the U.S. sovereign credit rating at "AA+" with a stable outlook, citing concerns over rising debt levels[29]

Core Viewpoint - The selection process for the 2025 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering has concluded, with a total of 639 valid candidates for the Chinese Academy of Sciences and 660 valid candidates for the Chinese Academy of Engineering [1][2]. Summary by Categories Chinese Academy of Engineering - The Chinese Academy of Engineering confirmed 660 valid candidates for the 2025 academician selection, categorized by various engineering departments [2][4]. - The distribution of candidates across different departments includes: - Mechanical and Transportation Engineering: 68 candidates - Information and Electronic Engineering: 68 candidates - Chemical, Metallurgical, and Materials Engineering: 71 candidates - Energy and Mining Engineering: 72 candidates - Civil, Hydraulic, and Architectural Engineering: 91 candidates - Environmental and Light Textile Engineering: 73 candidates - Agricultural Engineering: 83 candidates - Medical and Health Engineering: 91 candidates - Special Channel: 43 candidates [2][4]. Selection Process - The selection process for the academicians began on April 25, 2025, and the number of new academicians for both the Chinese Academy of Sciences and the Chinese Academy of Engineering is limited to no more than 100 each [2][4].

Core Viewpoint - The article emphasizes the importance of promoting the transfer of industries to the central and western regions of China as a means to upgrade industrial structure, promote regional coordinated development, and achieve carbon neutrality goals [1][2]. Economic Indicators - Gansu Province has seen an increase in the number and scale of industries transferring in, with its GDP and industrial added value accounting for 0.94% and 0.85% of the national total in 2023, respectively, up by 0.05 and 0.13 percentage points since 2020 [3]. - Since the "14th Five-Year Plan," 25 industrial categories have shown significant transfer into Gansu, an increase of 16 compared to the "13th Five-Year Plan," while only 4 categories have shown significant transfer out, a decrease of 9 [3]. - The revenue share and average employment share of Gansu's industrial enterprises have increased by 0.13 and 0.06 percentage points, respectively, since the "14th Five-Year Plan" [3]. Electricity Indicators - Gansu's electricity consumption has significantly increased due to industrial transfer, with industrial electricity consumption consistently above 70% of total electricity use, higher than the national average [4]. - The annual increase in electricity consumption due to industrial transfer in Gansu is approximately 10 billion kilowatt-hours [4]. New Energy Utilization - Gansu's new energy utilization rate is expected to improve significantly by 2030, with projections indicating that under enhanced industrial transfer scenarios, the overall utilization rate of new energy could increase by 1.0 to 3.8 percentage points [5][6]. - In 2025, the impact of industrial transfer on new energy consumption is less pronounced, but by 2030, the effect becomes significant, with potential increases in new energy generation of up to 70.2 billion kilowatt-hours [5][6]. Industrial Layout and New Energy - The layout of transferred industries significantly affects Gansu's new energy utilization rate, with a preference for locating in the Hexi region as the scale of transferred electricity increases [6][7]. - The article suggests that optimizing industrial layout and enhancing coordination between industrial development and new energy resources are crucial for maximizing new energy utilization [8]. Collaborative Development - The article advocates for a top-level design approach to optimize industrial layout and accelerate the coordinated development of new energy and industries [8]. - It emphasizes the need for regional collaboration to build a new power system and modern industrial framework in Northwest China, highlighting the importance of regional networks and shared resources [9].

国家药监局副局长杨胜8月22日在国新办举行的"高质量完成'十四五'规划"系列主题新闻发布会上介 绍，"十四五"期间，我国全方位筑牢药品安全底线，全链条支持医药产业高质量发展，全覆盖保障人民 群众用药需求。目前，我国医药产业规模位居全球第二位，在研创新药数目达到全球30%左右。"十四 五"以来，共批准387个儿童药品、147个罕见病药品上市，有效满足了重点人群的用药需求。 （来源：新华社） ...

Group 1: Energy and Coal - In July 2025, China's total electricity consumption reached 1,022.6 billion kWh, marking a year-on-year increase of 8.6%, the first time it has exceeded 1 trillion kWh in a single month [2] - The demand for thermal power increased, with industrial thermal power generation reaching 602 billion kWh in July, up 4.3% year-on-year and 21.9% month-on-month, boosting demand for thermal coal [2] - As of August 20, 2025, coal prices at Qinhuangdao Port reached 707 RMB/ton, a month-on-month increase of 10.6%, recovering 15.0% from the low of 615 RMB/ton on June 12 [2] Group 2: Oil and Gas - OPEC+ announced a significant increase in September production targets by 547,000 barrels per day, with additional quotas for the UAE, leading to a gradual decline in oil prices [3] - As of August 20, 2025, WTI and Brent crude oil futures prices fell by 9.5% and 7.8% respectively compared to the end of July, reaching 62.71 and 66.84 USD/barrel [3] - Long-term oil price support is expected from high-dividend energy companies with production and cost reduction capabilities, recommending China National Offshore Oil Corporation (CNOOC) and China Petroleum [3] Group 3: Petrochemicals - The global ethylene industry is undergoing a restructuring, with high-cost capacities in Europe, Japan, and South Korea being phased out, while low-cost capacities in the Middle East and the U.S. are increasing [4] - The supply-demand balance in the ethylene industry has not yet reached a turning point, but the global supply structure is shifting towards lower-cost regions [4] - Companies benefiting from this trend include Baofeng Energy, Satellite Chemical, and Hengli Petrochemical [4] Group 4: Securities and Wealth Management - The trading activity in the market has significantly increased, with new account openings leading to a drop in commission rates, some as low as 0.08% [5] - The average daily trading volume in A-shares reached 1,484.4 billion RMB, a 40% increase compared to 2024 [5] - Wealth management transformation is seen as a key to breaking through challenges, with potential for new growth through service upgrades and innovative tools [5] Group 5: Construction and Engineering - The Chinese government has emphasized the need to support the smooth construction and operation of existing PPP projects, which may alleviate the accounts receivable risks for construction companies [6] - The funding for these projects primarily relies on local special bonds, which may lead to competition between new and existing projects [6] - Recommended companies include China Railway Construction Corporation, China Communications Construction Company, and China State Construction Engineering [6] Group 6: Healthcare and Consumer Goods - The company Steady Medical reported a revenue of 5.296 billion RMB in the first half of 2025, a year-on-year increase of 31.3%, with a net profit of 492 million RMB, up 28.1% [8] - The company is expected to recover from the impact of the "315" industry incident, with core categories likely to continue driving growth [8] - The company is positioned as a dual-driven health enterprise, focusing on both consumer and medical sectors [8] Group 7: Internet and Technology - Kuaishou's second-quarter revenue reached 35 billion RMB, a year-on-year increase of 13%, exceeding market expectations [9] - The company is expected to accelerate B-end commercialization with the launch of a subscription plan in the third quarter [9] - The long-term penetration of AI applications in Kuaishou is anticipated to enhance its revenue streams [9] Group 8: Aviation and Transportation - China Civil Aviation Information Network reported a revenue of 3.895 billion RMB in the first half of 2025, a decrease of 3.6%, but a net profit increase of 5.9% to 1.448 billion RMB [15] - The company is expected to benefit from the steady growth in civil aviation demand and maintain its leading position in the industry [15] - The growth in aviation information technology processing volume is a positive indicator for future performance [15] Group 9: Chemicals and Materials - Kanglong Chemical reported a revenue of 6.441 billion RMB in the first half of 2025, a year-on-year increase of 14.9%, with a net profit of 756 million RMB, up 9.5% [16] - The company is expected to continue its positive growth trajectory due to strong demand in the industry and its robust core business capabilities [16] - The company maintains a "buy" rating based on its performance and market outlook [16] Group 10: Agriculture and Livestock - Minhe Livestock reported a revenue of 986 million RMB in the first half of 2025, a year-on-year decrease of 5.88%, with a net loss of 214 million RMB [27] - The company is facing pressure from falling chick prices, but there are signs of recovery in prices due to improved supply-demand dynamics [27] - The potential for price recovery and capacity reduction in the white-feathered chicken market is a key focus for future performance [27]